Skip to main content
Log in

Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Both body mass index (BMI) and breast density impact breast cancer risk in the general population. Whether obesity and density represent additive risk factors in women with lobular carcinoma in situ (LCIS) is unknown.

Methods

Patients diagnosed with LCIS from 1988 to 2017 were identified from a prospectively maintained database. BMI was categorized by World Health Organization classification. Density was captured as the mammographic Breast Imaging Reporting and Data System (BIRADS) value. Other covariates included age at LCIS diagnosis, menopausal status, family history, chemoprevention, and prophylactic mastectomy. Cancer-free probability was estimated using the Kaplan–Meier method, and Cox regression models were used for univariable and multivariable analyses.

Results

A total of 1222 women with LCIS were identified. At a median follow-up of 7 years, 179 women developed breast cancer (121 invasive, 58 ductal carcinoma in situ); 5- and 10-year cumulative incidences of breast cancer were 10% and 17%, respectively. In multivariable analysis, increased breast density (BIRADS C/D vs. A/B) was significantly associated with increased hazard of breast cancer (hazard ratio [HR] 2.42, 95% confidence interval [CI] 1.52–3.88), whereas BMI was not. On multivariable analysis, chemoprevention use was associated with a significantly decreased hazard of breast cancer (HR 0.49, 95% CI 0.29–0.84). Exploratory analyses did not demonstrate significant interaction between BMI and menopausal status, BMI and breast density, BMI and chemoprevention use, or breast density and chemoprevention.

Conclusions

Breast cancer risk among women with LCIS is impacted by breast density. These results aid in personalizing risk assessment among women with LCIS and highlight the importance of chemoprevention counseling for risk reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW, Jr. Lobular carcinoma in situ of the breast: Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol. 1978;2(3):225–51.

    Article  CAS  Google Scholar 

  2. Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.

    Article  CAS  Google Scholar 

  3. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.

    Article  CAS  Google Scholar 

  4. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.

    CAS  PubMed  Google Scholar 

  5. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627–33.

    Article  CAS  Google Scholar 

  6. King TA, Pilewskie M, Muhsen S, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52.

    Article  Google Scholar 

  7. Hussain M, Cunnick GH. Management of lobular carcinoma in situ and atypical lobular hyperplasia of the breast: a review. Eur J Surg Oncol. 2011;37(4):279–89.

    Article  CAS  Google Scholar 

  8. Frykberg ER. Lobular Carcinoma In Situ of the Breast. Breast J. 1999;5(5):296–303.

    Article  Google Scholar 

  9. Cheng P, Huang Q, Shou J, Hu G, Han M, Huang J. Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study. Oncotarget. 2017;8(61):103047–54.

    PubMed  PubMed Central  Google Scholar 

  10. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2002;75(3):259–68.

    Article  Google Scholar 

  11. Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20(10):3240–6.

    Article  Google Scholar 

  12. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227–36.

    Article  CAS  Google Scholar 

  13. Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res. 2007;9(6):217.

    Article  Google Scholar 

  14. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69.

    Article  Google Scholar 

  15. Tice JA, O’Meara ES, Weaver DL, Vachon C, Ballard-Barbash R, Kerlikowske K. Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst. 2013;105(14):1043–9.

    Article  CAS  Google Scholar 

  16. Reimers LL, Crew KD, Terry MB. Atypical hyperplasia of the breast. N Engl J Med. 2015;372(13):1270–1.

    PubMed  Google Scholar 

  17. Vierkant RA, Degnim AC, Radisky DC, et al. Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer. 2017;17(1):84.

    Article  Google Scholar 

  18. Byrne C, Schairer C, Brinton LA, et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control. 2001;12(2):103–10.

    Article  CAS  Google Scholar 

  19. Hudson S, Vik Hjerkind K, Vinnicombe S, et al. Adjusting for BMI in analyses of volumetric mammographic density and breast cancer risk. Breast Cancer Res. 2018;20(1):156.

    Article  Google Scholar 

  20. Soguel L, Durocher F, Tchernof A, Diorio C. Adiposity, breast density, and breast cancer risk: epidemiological and biological considerations. Eur J Cancer Prev. 2017;26(6):511–20.

    Article  Google Scholar 

  21. Baglietto L, Krishnan K, Stone J, et al. Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. Am J Epidemiol. 2014;179(4):475–83.

    Article  Google Scholar 

  22. Hart V, Reeves KW, Sturgeon SR, et al. The effect of change in body mass index on volumetric measures of mammographic density. Cancer Epidemiol Biomarkers Prev. 2015;24(11):1724–30.

    Article  Google Scholar 

  23. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278(17):1407–11.

    Article  CAS  Google Scholar 

  24. Schoemaker MJ, Nichols HB, Wright LB, et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 2018;4(11):e181771.

    Article  Google Scholar 

  25. King TA, Muhsen S, Patil S, et al. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013;142(2):445–53.

    Article  Google Scholar 

  26. Vachon CM, Pankratz VS, Scott CG, et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. 2015;107(5).

  27. American College of Radiology. Breast Imaging and Reporting and Data System (ACR BI-RADS® Atlas) teR, VA: American College of Radiology, 2013.

    Google Scholar 

  28. Chun J, El-Tamer M, Joseph KA, Ditkoff BA, Schnabel F. Predictors of breast cancer development in a high-risk population. Am J Surg. 2006;192(4):474–7.

    Article  Google Scholar 

  29. Cecchini RS, Costantino JP, Cauley JA, et al. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res (Phila). 2012;5(4):583–92.

    Article  CAS  Google Scholar 

  30. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.

    Article  CAS  Google Scholar 

  31. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.

    Article  CAS  Google Scholar 

  32. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090–5.

    Article  Google Scholar 

  33. Roetzheim RG, Lee JH, Fulp W, et al. Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast. 2015;24(1):51–6.

    Article  Google Scholar 

  34. Roche CA, Tang R, Coopey SB, Hughes KS. Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast J. 2019;25(2):190–5.

    Article  Google Scholar 

  35. Flanagan MR, Zabor EC, Stempel M, Mangino DA, Morrow M, Pilewskie ML. Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann Surg Oncol. 2019.

  36. DeCensi A PM, Guerrieri Gonzaga A, Avino F, Cortesi L, Donadio M, Pacquola M, Falcini F, Gulisano M, Digennaro M, Tienghi A, Cagossi K, Pinotti G, Varicchio C, Caviglia S, Boni L, Bonanni BEO. A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ. San Antonio Breast Cancer Symposium. 2018;abstract GS3-01.

  37. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012;7(12):e51446.

    Article  CAS  Google Scholar 

  38. Nakhlis F, Gilmore L, Gelman R, et al. Incidence of adjacent synchronous invasive carcinoma and/or ductal carcinoma in situ in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020). Ann Surg Oncol. 2016;23(3):722–8.

    Article  Google Scholar 

Download references

Acknowledgments

The preparation of this study was funded in part by NIH/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center. This study was presented in podium format at the Society of Surgical Oncology 72nd Annual Cancer Symposium, March 27–30, 2019, San Diego, CA. Dr. Tari A. King has received honoraria as a speaker for Genomic Health

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Melissa L. Pilewskie MD.

Ethics declarations

All other authors have no conflict of interest disclosures to report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minami, C.A., Zabor, E.C., Gilbert, E. et al. Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ?. Ann Surg Oncol 27, 1844–1851 (2020). https://doi.org/10.1245/s10434-019-08126-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-08126-9

Navigation